CD4 and myeloid sarcoma: Having identified LIF as a natural regulator of neuro-immune health, we developed LIFNano and demonstrated that (i) LIFNano-CD4 promotes antigen-specific Treg and suppresses TH17 immunity in vivo (1); (ii) LIFNano-CD4 promotes recovery from EAE in a stringent Biozzi mouse model of neuroprotection (2); (iii) LIFNano-NG2 is a highly potent inducer of myelin repair in vivo (3)—far superior to other myelinogenic agents; and (iv) LIFNano-CD4 partially reverses paralysis in the Hooke EAE model of progressive MS (manuscript in preparation).